Skip Navigation


JAC Advance Access originally published online on July 15, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/312    most recent
dkg329v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fisher, L. M.
Right arrow Articles by Heaton, V. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, L. M.
Right arrow Articles by Heaton, V. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 312-313
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Analysis of dual active fluoroquinolones in Streptococcus pneumoniae

L. Mark Fisher1,*, Katherine A. Gould1, Xiao-Su Pan1, Sandhiya Patel1 and Victoria J. Heaton2

1 Molecular Genetics Group, Department of Basic Medical Sciences—Biochemistry and Immunology, St. George’s Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE; 2 Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS, UK

Keywords: Streptococcus pneumoniae, fluoroquinolones, DNA gyrase, topoisomerase IV, dual activity

The first 10% of the full text of this article appears below.

Sir,

A recent review by Smith et al.1 and associated correspondence2,3 raised important unresolved issues regarding which quinolones exert dual activity through gyrase and topoisomerase IV in Streptococcus pneumoniae. Dual action involves the substantial engagement of both enzyme killing pathways and is of particular interest in potentially limiting the emergence of resistance. Smith et al.3 concur with us2 that genetic studies are very important in identifying dual active drugs and agree that clinafloxacin is . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. T. Black, T. Stachyra, D. Platel, A.-M. Girard, M. Claudon, J.-M. Bruneau, and C. Miossec
Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3339 - 3349.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. A. Gould, X.-S. Pan, R. J. Kerns, and L. M. Fisher
Ciprofloxacin Dimers Target Gyrase in Streptococcus pneumoniae
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2108 - 2115.
[Abstract] [Full Text] [PDF]